🎉 M&A multiples are live!
Check it out!

Citius Oncology Valuation Multiples

Discover revenue and EBITDA valuation multiples for Citius Oncology and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Citius Oncology Overview

About Citius Oncology

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products.  In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.


Founded

2021

HQ

United States of America
Employees

n/a

Website

citiusonc.com

Financials

LTM Revenue $15.5M

LTM EBITDA n/a

EV

$51.3M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Citius Oncology Financials

Citius Oncology has a last 12-month revenue of $15.5M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Citius Oncology achieved revenue of n/a and an EBITDA of -$20.6M.

Citius Oncology expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Citius Oncology valuation multiples based on analyst estimates

Citius Oncology P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$12.1M -$20.6M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$5.4M -$12.7M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Citius Oncology Stock Performance

As of April 15, 2025, Citius Oncology's stock price is $1.

Citius Oncology has current market cap of $47.5M, and EV of $51.3M.

See Citius Oncology trading valuation data

Citius Oncology Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$51.3M $47.5M XXX XXX XXX XXX $-0.31

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Citius Oncology Valuation Multiples

As of April 15, 2025, Citius Oncology has market cap of $47.5M and EV of $51.3M.

Citius Oncology's trades at 3.3x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Citius Oncology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Citius Oncology and 10K+ public comps

Citius Oncology Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $51.3M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E n/a XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Citius Oncology Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Citius Oncology Valuation Multiples

Citius Oncology's NTM/LTM revenue growth is 239%

Citius Oncology's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Citius Oncology's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Citius Oncology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Citius Oncology and other 10K+ public comps

Citius Oncology Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 70% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Citius Oncology Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Citius Oncology M&A and Investment Activity

Citius Oncology acquired  XXX companies to date.

Last acquisition by Citius Oncology was  XXXXXXXX, XXXXX XXXXX XXXXXX . Citius Oncology acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Citius Oncology

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Citius Oncology

When was Citius Oncology founded? Citius Oncology was founded in 2021.
Where is Citius Oncology headquartered? Citius Oncology is headquartered in United States of America.
Who is the CEO of Citius Oncology? Citius Oncology's CEO is Mr. Leonard L. Mazur.
Is Citius Oncology publicy listed? Yes, Citius Oncology is a public company listed on NAS.
What is the stock symbol of Citius Oncology? Citius Oncology trades under CTOR ticker.
When did Citius Oncology go public? Citius Oncology went public in 2024.
Who are competitors of Citius Oncology? Similar companies to Citius Oncology include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Citius Oncology? Citius Oncology's current market cap is $47.5M
What is the current revenue of Citius Oncology? Citius Oncology's last 12-month revenue is $15.5M.
What is the current EV/Revenue multiple of Citius Oncology? Current revenue multiple of Citius Oncology is 3.3x.
Is Citius Oncology profitable? Yes, Citius Oncology is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.